Update on genomic and molecular landscapes of well-differentiated liposarcoma and dedifferentiated liposarcoma

Lu, Jun; Wood, David; Ingley, Evan; Kõks, Sulev; Wong, Daniel

doi:10.1007/s11033-021-06362-5

Cited by 17 publications

(28 citation statements)

References 100 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…Molecular alterations of WDLPS are characterized by a supernumerary ring and giant marker chromosomes with amplified sequences from the 12q14-15 region (notably containing MDM2 and CDK4 genes among others) [ 22 , 23 , 24 ]. Ancillary studies that are frequently used to help support the diagnosis of WDLPS include immunohistochemistry to stain for the nuclear expression of MDM2 or CDK4 proteins, or fluorescence in-situ hybridization (FISH) to quantify the corresponding gene amplifications [ 25 , 26 , 27 ].…”

Section: Liposarcoma (Lps)mentioning

confidence: 99%

Updates in Pathology for Retroperitoneal Soft Tissue Sarcoma

Mack

Purgina

2022

Current Oncology

View full text Add to dashboard Cite

Retroperitoneal tumors are extremely rare. More than 70% of primary retroperitoneal soft tissue tumors are malignant. The most common sarcomas in the retroperitoneum include liposarcomas and leiomyosarcoma, however other sarcomas, along with benign mesenchymal tumors, can occur. Sarcomas are a heterogenous group of tumors with overlapping microscopic features, posing a diagnostic challenge for the pathologist. Correct tumor classification has become important for prognostication and the evolving targeted therapies for sarcoma subtypes. In this review, the pathology of retroperitoneal soft tissue sarcomas is discussed, which is important to the surgical oncologist. In addition, less common sarcomas and benign mesenchymal tumors of the retroperitoneum, which may mimic sarcoma clinically and pathologically, are also discussed.

show abstract

Section: Liposarcoma (Lps)mentioning

confidence: 99%

Updates in Pathology for Retroperitoneal Soft Tissue Sarcoma

Mack

Purgina

2022

Current Oncology

View full text Add to dashboard Cite

show abstract

“…However, if WD-LPS patients are improperly handled in the early clinical stage and tumor recurs repeatedly, it may transform into DD-LPS. WD-LPS has no metastatic potential unless it transforms into DD-LPS, which is a nonlipomatous tumor [ 4 ]. DD-LPS has a more aggressive behavior compared to WD-LPS and has a high possibility of local recurrence reported to be about 85% [ 5 ].…”

Section: Introductionmentioning

confidence: 99%

Evaluation of Efficacy of Adjuvant Radiotherapy in Well-Differentiated Liposarcoma Patients with Positive Surgical Margins: A Population-based Study

Wang

Chen

Cen

et al. 2022

Journal of Oncology

View full text Add to dashboard Cite

Background. The use of adjuvant radiotherapy (RT) for well-differentiated liposarcoma (WD-LPS) patients with positive surgical margins is unclear. We aim to compare the overall survival (OS) and cancer-specific survival (CSS) of well-differentiated liposarcoma patients with positive surgical margins in an RT group and non-RT group. Methods. WD-LPS patients with positive margins from 2000 to 2018 were extracted from the Surveillance, Epidemiology, and End Results (SEER) database and divided into two groups: RT group and non-RT group. Kaplan–Meier survival analysis with the log-rank test was performed to evaluate the difference of overall survival (OS) and cancer-specific survival (CSS) between groups. Univariate and multivariate Cox proportional hazard analyses were performed to identify important prognostic factors of OS and CSS. Analyses were adjusted using propensity-score matching. Results. We identified 2549 patients: 377 (14.79%) with RT and 2172 (85.21%) without RT. The median age was 61 years, and the median follow-up time was 68 months. The log-rank test revealed that there was no significant difference of CSS between RT and non-RT groups ( P = 0.81 ). The 5-year and 10-year CSS were comparable ( P = 0.418 and P = 0.987 ). Additionally, the use of RT was neither an independent prognostic factor for OS nor CSS. Age, sex, tumor site, the use of chemotherapy were independent prognostic factors for OS after propensity score matching, while race and the tumor site were independent prognostic factors for CSS. Conclusion. Adjuvant RT had no significant improvement on OS and CSS of WD-LPS patients with positive surgical margins.

show abstract

“…DDLPS usually affects elderly patients, and the most common site is the retroperitoneum, followed by the extremities [1][2][3][4]. Genetically, DDLPS is characterized by the amplification of MDM2 and CDK4 at 12q13-15 and by ALT/WDLPS [1,2,[4][5][6]. In addition, multiple gene amplifications at 12q13-15, such as those of HMGA2, TSPAN31, and CPM, have also been identified in DDLPS [2,[4][5][6][7].…”

Section: Introductionmentioning

confidence: 99%

“…Genetically, DDLPS is characterized by the amplification of MDM2 and CDK4 at 12q13-15 and by ALT/WDLPS [1,2,[4][5][6]. In addition, multiple gene amplifications at 12q13-15, such as those of HMGA2, TSPAN31, and CPM, have also been identified in DDLPS [2,[4][5][6][7]. Copy number alterations (CNAs) have been reported in chromosomes other than 12q13-15, and the amplification of 1p32 and 6q23 and the loss of 11q22-24 are frequently observed [8][9][10][11].…”

Section: Introductionmentioning

confidence: 99%

“…Although complete resection is the primary modality, it is often difficult to achieve in cases involving the retroperitoneum because of the adjacent blood vessels or organs, 2 of 15 leading to poorer prognosis than in cases arising in the extremities [3,12]. Moreover, the distant metastasis rate is as high as 15-30%, resulting in an overall mortality rate of 28% [5]. Systemic chemotherapy is considered in unresectable or metastatic cases, but DDLPS is known to be insensitive to conventional chemotherapy [13,14].…”

Section: Introductionmentioning

confidence: 99%

See 1 more Smart Citation

Establishment and Characterization of NCC-DDLPS4-C1: A Novel Patient-Derived Cell Line of Dedifferentiated Liposarcoma

Tsuchiya

Yoshimatsu²,

Noguchi³

et al. 2021

JPM

View full text Add to dashboard Cite

Dedifferentiated liposarcoma (DDLPS) is a highly malignant sarcoma characterized by the co-amplification of MDM2 and CDK4. Although systemic chemotherapy is recommended for unresectable or metastatic cases, DDLPS is insensitive to conventional chemotherapy, leading to an unfavorable prognosis. Therefore, novel treatment methods are urgently required. Patient-derived cell lines are essential in preclinical studies. Recently, large-scale screening studies using a number of cell lines have been actively conducted for the development of new therapeutic drugs. However, the DDLPS cell line cannot be obtained from public cell banks owing to its rarity, hindering screening studies. As such, novel DDLPS cell lines need to be established. Accordingly, this study aimed to establish a novel DDLPS cell line from surgical specimens. The cell line was named NCC-DDLPS4-C1. NCC-DDLPS4-C1 cells retained copy number alterations corresponding to the original tumors. Further, the cells demonstrated constant growth, spheroid formation, and equivalent invasiveness to MG63 osteosarcoma cells. We also conducted drug screening and integrated the results with those of the previously reported DDLPS cell lines. Consequently, we identified the histone deacetylase inhibitor romidepsin as a novel candidate drug. In conclusion, the NCC-DDLPS4-C1 cell line is a useful tool for the basic study of DDLPS.

show abstract

Update on genomic and molecular landscapes of well-differentiated liposarcoma and dedifferentiated liposarcoma

Cited by 17 publications

References 100 publications

Updates in Pathology for Retroperitoneal Soft Tissue Sarcoma

Updates in Pathology for Retroperitoneal Soft Tissue Sarcoma

Evaluation of Efficacy of Adjuvant Radiotherapy in Well-Differentiated Liposarcoma Patients with Positive Surgical Margins: A Population-based Study

Establishment and Characterization of NCC-DDLPS4-C1: A Novel Patient-Derived Cell Line of Dedifferentiated Liposarcoma

Contact Info

Product

Resources

About